Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Tauopathies 2Neurodegenerative Diseases 2Nervous System Diseases 2Mental Disorders 2Inflammation 2Dementia 2Central Nervous System Diseases 2Brain Diseases 2Alzheimer Disease 2Neurocognitive Disorders 1Cognitive Dysfunction 1

Interventions

Patient Reported Outcome Measures 2Neuropsychological Tests 2lithium sulfate 1XENP 1595 1Tablets 1Sodium Chloride 1Ramipril 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Quality of Life 1Pioglitazone 1Metformin 1Mental Status and Dementia Tests 1Memantine 1Lithium 1G(M1) Ganglioside 1Donepezil 1Climate Anxiety 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cognitive Dysfunction × XENP 1595 × CNS × Clear all
NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡